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Preterm birth (PTB) (<37 weeks of gestation) is the second largest direct cause of mortality in 
children under the age of five. Infants born preterm often have various medical complications, 
including neurological disorders, leading to increased morbidity. PTB is multifactorial and few 
efficacious therapies exist. Currently, the only therapeutic that has shown efficacy against PTB is 
progesterone. Vaginal drug delivery is the preferred route for targeting the female reproductive 
tract. With effective localized delivery, vaginally delivered drugs have a high permeation range, 
avoid first pass metabolism, and experience lower enzymatic activity, which leads to an 
increased drug concentration in local tissues. However, key barriers to effective vaginal drug 
delivery, including the protective cervicovaginal mucus (CVM) that acts as a barrier and 
facilitates clearance, must be considered. Clinically, progesterone is often dosed vaginally for the 
prevention of preterm birth (PTB). Crinone® is a hypertonic gel containing micronized 
progesterone used for this purpose. The prevention of PTB with Crinone® has varied efficacy, 
likely due to its formulation which is hypertonic and micronized. Here, I describe a novel in-situ 
hydrogel for vaginal progesterone delivery that demonstrates more superior physical properties 
in terms of particle size, osmolality, surface charge and viscoelastic profile when compared to 
Crinone®.  
 
Previous studies have demonstrated that non-adhesive mucus penetrating particles (MPP) (with 
hydrophilic arms and a hydrophobic core) can effectively overcome the CVM to deliver drug 
loads to the underlying epithelium. However, due to liquid formulation MPP alone is not the 
most desirable mode of delivery. Here, I tested whether an in-situ hydrogel composed of 
progesterone loaded MPP could serve as a more effect mode of drug delivery. I hypothesized 
that Pluronic F127, a nonionic amphiphilic triblock copolymer with thermoreversible properties 
based on concentration, could create an in-situ gel upon vaginal delivery. Nanoparticles were 
developed using various Pluronics and the most desirable nanoparticle formulation was selected 
based size, ζ-potential, polydispersity and tonicity. Separately, various F127 gels were 
characterized for rheological properties such as sol-gel transition. Finally, nanoparticles and gels 
were combined and further tested for physical characteristics and in vivo properties. I found that 
nanoparticles with lower concentrations milled at higher volumes with ZsOBO5 beads with low 
concentrations of stabilizer had the smallest size, PDI, and ζ-potential, as desired. F127 gels from 
 
 iii 
14-18% w/w demonstrated the most desirable physical properties based on rheological and in 
vivo tests. Of all the hydrogels tested the 16% w/w gel with 2% F127 and 2% F68 coated NC had 
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Introduction and Background  
The Significance of Preterm Birth  
 
The World Health Organization estimates that every year approximately 15 million babies are 
born prematurely, the highest rates occur in Africa and North America. One million of those 
babies die from complications related to preterm delivery [1]. Preterm birth (PTB) is the leading 
cause of mortality and morbidity in children under the age of five. PTB can cause brain injury 
via neuroinflammation resulting in a cascade of central nervous system responses which causes 
damage to the developing brain [2-3]. In 2016, PTB affected approximately 10% of infants in the 
United States [4]. Not only does PTB have significant societal ramifications, the medical cost of 
associated with care exceeds $25 billion per annum [5]. While there are multiple drugs on the 
market to prevent PTB, including the only FDA approved drug solely designated for this 
purpose, hydroxyprogesterone caproate (Makena); the main vaginal delivery drug, Crinone®, 
has low and varied efficacy ranging from 33.1% to up to 58.1% in clinical pregnancies [6]. 
Therefore, it is imperative that we find a tolerable and efficacious alternative to address this 
problem. While the causes of PTB vary and some of them are not fully understood, we know that 
the progesterone inflammation pathway plays a significant role in causing preterm labor.  
 
Physiological Challenges Associated with Localized Vaginal Delivery 
The Role of Cervicovaginal Mucus in the Context of Vaginal Delivery  
 
The mode of administration is also of critical importance when treating PTB. Vaginal delivery 
offers many advantages over other routes of administration: effective localized delivery, huge 
permeation range, large vascularization, avoidance of first pass metabolism and lower enzymatic 
activity [7]. The female reproductive tract (FRT) is covered in cervicovaginal mucus (CVM) 
which makes vaginal delivery particularly challenging. A clear understanding of vaginal 
physiology and anatomy is essential for the development of localized drug delivery platforms. 
The mucus is a viscoelastic gel layer that protects tissues from the external environment. The 
CVM is composed of a mesh of interwoven mucin fibers, proteins, cells, lipids and bacteria [8]. 
Each of the components works together to form a nanoscopic heterogenous environment that 
functions as the critical barrier against pathogens. Typically, there are steric interactions as well 
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as the physical restrictions of pores that are a challenge for local delivery of xenobiotics. The 
CVM has an average pore size of 340nm +/- 70nm, desirable nanoparticles would have a smaller 
hydrodynamic diameter [8]. In previous mucus studies conducted at the Center for 
Nanomedicine (CNM), we have seen as pregnancy progress the size of the pores decreases. 
Additionally, during pregnancy the mucus thickens forming a plug that protects the uterus and 
the growing fetus changing the physical landscape of the CVM [9]. Factors such as 
infections/diseases and physical stressors can also affect the microbiome of the CVM leading to 
a reduction in barrier properties [8]. 
 
CVM plays a significance role in the female reproductive tract (FRT) by acting as a constant 
barrier against foreign pathogens and rapidly clearing any particulates from the system. Forty 
percent of preterm births are caused by some form of intrauterine infection and typically results 
in a gestation of 32 weeks or less [10]. In such cases a microbial infection reaches the amniotic 
cavity causing PTB. In healthy patients, high progesterone levels during pregnancy lead to a 
strengthening of the mucus plug which covers the cervix to prevent pathogens and infections 
from reaching the uterus. However, when the mucus barrier is comprised by mechanisms such as 
those involved in bacterial vaginosis, the impaired CVM may lead to increased risk of PTB [11].  
Thus, when developing a therapy for PTB we must consider the role of mucosal barrier and 
delivery through the mucosal pores.  
 
The Role of Epithelial Lining for Drug Delivery 
 
The vaginal epithelium is composed of distinct layers of apical, lateral and basal plasma 
membranes. Epithelial polarity has two functional directions from apical into the basolateral 
region or basolateral to apical permeability. The direction of polarity is impacted by multiple 
factors, including P-gp substrate mediated transport, that increases apical to basolateral 
permeability and decreases basolateral to apical permeability. Mucosal epithelia also rely heavily 
on osmotic gradients to mediate transport. Osmotic driven secretions of vaginal products have 
been shown to have a rate proportional to the hypertonicity of the given formulation in vivo. 
Secretions not only cause immediate loss of the product but also produce local inflammation and 
cause discomfort in patients. Therefore, fluid uptake and secretion can be controlled through 
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changes in tonicity of the vaginally delivered product. The Ensign lab has previously 
demonstrated that hypotonic formulations of nanoparticles (MPP) increase fluid absorption and 
thus causing convective transport of drug loaded nanoparticles to the vaginal epithelium [12].   
   
 
As previously described, MPPs rapidly diffuse through mucosal barriers to reach the underlying 
squamous epithelial cells. Comparatively, conventional particles (CPs) are trapped in vaginal 
mucus. CPs are trapped due to steric hinderance and interactions with hydrophobic particles and 
hydrophobic regions within mucin fibers. As previously reported by the Ensign lab, MPPs have a 
muco-inert coating that allow particles up to 500nm in diameter to penetrate the CVM. 
Nanoparticles and other xenobiotics that cannot diffuse through the mucus layer are trapped 
within mucus and cleared between minutes and up to hours as seen in Figure 1 A. Effective 
delivery of NP gel within the CV tract requires the delivery system to penetrate the mucosal 
barrier without rapid clearance. This problem could be mitigated through a thermoreversible gel 
with desirable sol-gel properties would also be advantageous because it forms in situ allowing 
for higher retention.  
 
Characteristically mucus is shear thinning and has a rapidly clearing top layer over a slowly 
cleared adherent layer of mucus above the apical level of epithelial cells. Therefore, particles 
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need to diffuse quickly through to penetrate rapidly cleared mucus layer to reach the underlying 
adherent mucus layer. Loaded MPPs can rapidly diffuse through the CVM to reach the epithelia 
and provide sustained release of their payload. MPP are specifically formulated to penetrate the 
mucosal barriers due to their high density and low molecular weight polyethylene glycol coating. 
PEG is uncharged and thus muco-inert which subsequently avoids steric and ionic interactions. 
The MPP does not adhere to hydrophobic and charged regions of mucin allowing PEG coated 
MPP to slip through pores in the CVM. Although the PEG coating increases the hydrodynamic 
diameter, the neutral surfaces mitigate “trapping” effects of mucus. Other diblock co-polymers, 
Pluronics, are commonly used for covalent linkages and coatings in MPP.  
 
Current Therapies and the Associated Challenges  
 
Currently, the only FDA approved therapeutic active ingredients that has shown efficacy against 
PTB are progesterone and its synthetic analogs [13]. Progesterone plays a natural role in the 
establishment and maintenance of pregnancy [14]. The pharmacological action of progesterone 
(P4) is to inhibit cervical ripening and prevent delivery. In humans, functional progesterone 
withdrawal signals the end of pregnancy [15]. It has been theorized that progesterone 
supplementation could lead to a more anti-inflammatory state and consequently prevent PTB. A 
successful drug candidate would be able to reduce the inflammation associated with PTB.  
 
Conventional vaginal gel products consist of particles that are 1 micron or larger in size making 
it difficult for them to pass through the pores of the CVM and thus rendering them ineffective. 
Crinone®, a micronized progesterone gel, is currently approved for vaginal administration and 
has been used in clinical studies for pre-term birth [16-17, 6]. During a randomized, double blind 
placebo-controlled trial daily dosing of Crinone® reduced the rate of PTB before 33 weeks by 
only 44% [16]. Furthermore, vaginal gel products are typically hypertonic, causing fluid 
secretions and subsequently rapid clearance of drug from the vagina. Using Crinone® many 
women have reported discharge and discomfort, consequences of localized toxicity and 
inflammation, which counteracts the anti-inflammatory properties many researchers aim to prove 
with progesterone formulations [18]. The negative effects associated with hypertonic gels can 
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also increase the risk of bacterial vaginosis (BV) and other infections, which are known risk 
factors for preterm labor. 
 
The Use of Pluronics and Polymeric Stabilizers  
 
With topically delivered formulations drug failure in clinic is typically due to the hydrophobicity 
and low bioavailability of drug candidates. Nanocarriers offer a method of encapsulation that 
manipulates hydrophobic drugs and confines them into nanoscale particles which can be used in 
a stable homogenous suspension. Thus, allowing for more applicable clinical use. Poloxamers or 
Pluronics have been used in the biomedical field for a wide variety of applications including by 
not limited to emulsifiers, additives, surfactants and permeation enhancers. Pluronics are a group 
of synthetic nonionic block copolymers composed of a central chain of hydrophobic 
poly(propylene oxide) flanked by two hydrophilic chains of poly(ethylene oxide). Each Pluronic 
has a A-B-A triblock structure consequently giving them an amphiphilic structure as seen in 
Figure 2. Each Pluronic triblock polymer is named by letter and a proceeding two or three digits. 
The letter refers to the physical form of the copolymer at room temperature (F for flake, P for 
paste and L for liquid). While the first number corresponds to the PPO molecular weight and the 
last number represents the percentage of PEO molecular weight of the total molecular weight.   
 




A common Pluronic, Pluronic F127, is hydrophilic coblock polymer of PEO (100)- PPO (65)- 
PEO (100). Due to F127’s amphiphilic characteristics they possess surfactant properties which 
allow them to interact with hydrophobic surfaces as well as biological membranes [19].  
Additionally, being amphiphilic allows Pluronic to combine and form micelles, with a 
hydrophobic core and a hydrophilic shell, in aqueous solutions. Pluronic mixed in an aqueous 
solution with drug can act as a surfactant, coating and loading the drug into the hydrophobic 
core, thus creating nanoparticles [20]. Properties such as particle stability (measured through zeta 
potential) and hydrodynamic diameter can be optimized through the use of specific Pluronics and 
stabilizers as well as conditions like type of mixing (wet milling vs high pressure 
homogenization) and mixing time. For our purposes a variety of Pluronics and stabilizers were 
used, while mixing conditions were unchanged. 
 
Pluronic F68 is a non-ionic surfactant that is frequently used to control shear forces in 
suspensions. The difunctional co-block polymer has been previously been used to increase pore 
formation and optimize drug releasing character of nanosuspensions. Pluronics generally have 
desirable biological activity; specifically, they are able to incorporate into membranes, 
translocate into cells and subsequently effect various cellular functions including mitochondrial 
respiration and ATP synthesis. Both of which have been studied extensively for absorption and 
drug interactions. F68 inhibits P-gp and CYP3A4 which leads to a reduction in metabolism 
hence decreasing drug interactions as described by Cornaire and Gonzalez and decreasing 
variability of the absorption site [21-22].     
 
d-alpha-tocopheryl poly (ethylene glycol) 1000 succinate (TPGS) is a safe pharmaceutical 
adjuvant. TPGS is a water-soluble derivative of vitamin E that is commonly used in the 
pharmaceutical and nutraceutical industries to enhance the bioavailability of poorly soluble 
active molecules. TPGS offers the benefits of both PEG and vitamin E in various nanocarriers 
for drug delivery including extended half life and enhanced cellular uptake. Additionally, the 
amphiphilic structure, a lipophilic alkyl tail and a hydrophobic polar head allows for a low 
critical micelle concentration of 0.02% w/w [23].  Previous studies have reported that TPGS is 
ideal for prodrug, micellular, liposomal and nanoparticle delivery with sustained, controlled and 
targeted applications. Across industry and research, TPGS has been used as an absorption 
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enhancer, additive, solubilizer, emulsifier, permeation enhancer and stabilizer. Feng et al 
describes a TPGS based nanoparticle copolymer system loaded with taxol or doxorubicin that 
increased uptake efficiency in Caco-2, HT-29, MCF-7 and C6 glioma cells. Furthermore, when 
used as a surfactant, TPGS was used to created emulsified nanospheres along with PLGA. As an 
additive for nanoparticles both encapsulation efficiency (EE) and sustained release were 
increased. Encapsulation efficiency increased from 69.0% to 75.9% with 4.2 drug loaded with 
the addition of 5% TPGS and 90.1% EE was achieved with 2% drug and 5% TPGS [23-24].  
 
Additionally, TPGS and some other co-block have been shown to inhibit P-glycoprotein (P-gp) 
activity. P-gp is found primarily in the apical surface of epithelial cells and as part of the ATP-
binding cassette (ABC) transporters it acts as a physiological barrier by binding therapeutics 
substrates. P-gp is responsible for efflux membrane transfer by limiting cellular uptake and 
distribution of xenobiotics and thus mediating drug-drug interactions [25].  
 
Additionally, I utilized HS 15 which is a potent non-ionic solubilizer and emulsifying agent with 
low toxicity. HS 15 is a low molecular weight agent used in the manufacture of aqueous 
parenteral formulations that is composed of polyglycol mono and lipophilic dierters of 12 
hydroxystearic acid and 30% hydrophilic free PEG. HS 15 has a high solubilization capacity, 
low viscosity, thermos stability, good biocompatibility and desirable micellular properties.       
 
Pluronic as a Hydrogel Platform  
 
Additionally, concentrated solutions of Pluronic have a thermoreversible gelation property: they 
are able to transition, in a certain temperature region, from a viscous liquid to an assembly of 
effectively crosslinked molecules while maintaining elasticity. The sol-gel transition temperature 
is governed by concentration, molecular weight and composition of each block polymer [26]. 
Therefore, thermosensitive Pluronic hydrogels have attracted significant interest in the scientific 
community and have been used for a variety of applications ranging including food products, 




Despite the frequent use of thermoreversible hydrogels in pharmaceutics and medicine, few 
studies have utilized in situ hydrogels for vaginal delivery. Furthermore, I investigated the use of 
mucus penetrating particles in combination with a hydrogel.  
 
 






The CVM’s mesh of mucin proteins forms a hydrophobic and charged net to sterically hinder 
foreign entities. The CNM has previously characterized the barrier properties of the CVM in 
healthy, non-pregnant women and shown that trapping occurs with conventional particles greater 
than 100nm. Furthermore, our collaborator, Dr. Richard Cone, has demonstrated viruses and 
pathogens can diffuse through the mucosal layer rapidly, indicating that the surface chemistry 
also impacts mobility in the CVM [31]. Therefore, in order to design an effective mucus 
penetrating drug platform it must have specific properties including size characteristics and 
surface chemistries that facilitate diffusion through the CVM. This led us to the design non-
adhesive mucus penetrating particles (MPPs) (with hydrophilic arms and a hydrophobic core). I 
was then able to investigate the effect of MPPs and fluorescently labelled virions in samples of 
CVM from healthy subjects. I used an imaging technique that allowed us to track hundreds of 
particles in a sample called multiple particle tracking (MPT). Using this method, I determined 
that CVM mesh pores were larger than previously published data had suggested [32]. MPPs as 
large as 500nm could diffuse through mucus. Further investigation showed us that healthy 
vaginal mucus adhesively traps herpes simplex virus (HSV) and human immunodeficiency virus 
(HIV), which helps to explain why health vaginal microbiota reduces the risk of sexually 
transmitted infections [20]. Based on these findings I could sufficiently quantify the structural 
and barrier properties of the CVM in hormonal and diseased states. Our group at the CNM used 
the average mean square displacements (MSD) as a function of time to illustrate the diffusion of 
nanoparticles and HIV over time. MSD is calculated by transforming the coordinates of 
nanoparticle centroids into time averaged MSD. 
< ∆𝑟2(𝜏) > = [𝑥(𝑡 + 𝜏) − 𝑥(𝑡)]2 + [𝑦(𝑡 + 𝜏) − 𝑦(𝑡)]2…………………………….Equation 1 
where x and y represent the 2D nanoparticle coordinates at a given time and t is the time scale 
[33]. Previously the static error has been estimated to 20 nm, and we assume that time scale of 1 
s is relatively long to the interval between frames to reduce the contributions of dynamic error 
[12, 33-34]. As shown in Figure 4, 100nm MPP can diffuse through the CVM of both healthy 
and BV women at similar rates [35]. Conventional particles (CP) of 100 nm, in comparison, 
diffuse much more slowly in healthy mucus, while BV secretions have reduced adhesive 
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trapping of CP. Thus, particles below 500 nm and ideally, in a range of 200 nm to 100 nm have 





MPP were prepared using a previously reported method on wet milling nanocrystal synthesis 
using a bead-based tissue homogenizer by Hoang et al [36]. Initial optimizations included 
varying bead type, F127 concentration, the inclusion of additional stabilizers and the total 
volume of solution. Briefly, various progesterone MPPs were made at concentrations of 2% w/w, 
4% w/w and 6% w/w F127 alone or with 2% TPGS, 2% F68 or 2% HS15 all obtained from 
BASF. This totaled to 90 unique combinations of progesterone nanoparticles.  
 
Zirconium beads were used as agitators in the milling process. Zirconium silicate (ZsOB5, 0.5 
mm diameter) and Zirconium oxide beads (ZrOB05, 0.5 mm diameter and ZrOB015, 0.15 mm 
diameter) from NextAdvance were loaded into 2 mL, 1.5 mL and 0.5 mL Eppendorf tubes for a 
total mass of 2000 mg, 1500 mg and 1000 mg, respectively. Pluronic F127, P4 and the additional 
stabilizer were loaded into tubes. Based on the tube size, 1.5 mL, 1.0 mL or 0.5 mL of deionized 
water was added to suspend the mixture. The solution was kept at 4°C overnight and 
subsequently wet milled for a total of ten hours. Every 2 h size and polydispersity index (PDI) 
 
 11 
measurements were taken. At 10 h ζ-potential was measured. The nanosuspensions were kept at 
4°C and stability measurements (ζ-potentials, size, PDI) were taken at 24 h, 48 h, 72 h and 168 h.  
 
Both the hydrodynamic diameters and ζ-potentials of the nanoparticle formulations were 
characterized by dynamic light scattering and laser Doppler anemometry, respectively. The sizes 
of the NP were determined using Zetasizer Nano ZS90 (Malvern Instruments, Southborough, 
MA). Size measurements were performed at 25°C at a scattering angle of 90°. To determine the 
ζ-potential particles were diluted in a 10mM NaCl solution diluted from Dulbecco’s phosphate-
buffered saline (Cellgro, Mediatech, Inc., Manassas, VA) at pH 7. ζ-potentials were measured by 
laser Doppler anemometry using Zetasizer Nano ZS. All measurements were performed in 
accordance to instrument instructions.  
 
Osmolality was measured using Wescor EliTechGroup Vapor vapor pressure Osmometer. The 
device was calibrated with 100, 290 and 1000 mOsm/kg solutions. After calibration, 10 µL of 
undiluted NS was measured.  
 
Results and Discussion 
 
The hydrodynamic diameter and PDI of the 90 formulations were measured and the mean size 
was determined at all time points. Formulations with that maintained a size below 350 nm from 
10 h to 168 h were selected as potential candidates.  Nanosuspensions that consisted of 2% w/w 
F127 either with stabilizer or without typically had a smaller diameter ranging from 233-380 nm, 
in comparison to >388 nm diameters of formulations with 4% w/w F127 and 6% w/w F127. 
Additionally, 2% w/w F127 nanosuspensions made with the ZsOB5 beads had smaller diameters 
when compared to formulations milled with ZrOB05 and ZrOB015 beads. PDI was measured to 
determine the heterogeneity of the given NC samples. NC with the PDI Ð < 200 were further 
selected from the 90 formulations.    
 
The ζ-potentials at 10 h, 24 h, 48 h, 72 h and 168 h were found for all formulations. The 
nanosuspensions that demonstrated the most neutral net charge were selected from the list of NS 





With size, PDI and ζ-potentials the “top five” NS could be found as seen in Table 1. 
Additionally, the osmolality of these formulations was measured to confirm their tonicity. 
Osmolality of all of the selected nanosuspensions were hypotonic. As previously reported 
hypotonic solutions enhances vaginal delivery by increasing fluid uptake into the vaginal 
epithelium [37].   
 
 
Formulation  Size (nm)  ζ-potential 
(mV) 
Osmolality (mOsm/kg)  
NC 2% F127 297 ± 16  -1.81 ± 0.15 7 ± 1.53 
NC 2% F127 + 2% 
TPGS 
320 ± 11 -1.48 ± 0.55 11 ± 3.00 
NC 2% F127 + 2% 
F68 
257 ± 12 -1.04 ± 0.26 18 ± 2.08 
NC 2% F127 + 2% 
HS15 
322 ± 18 -1.13 ± 0.74 19 ± 1.15 
NC 4% F127 229 ± 4 -0.762 ± 0.63 12 ± 11.93 
    
Table 1: Physical properties of selected progesterone nanoformulations. After milling the progesterone loaded NC coated with 











Intra-vaginal drug delivery is highly desirable for localized drug delivery to the female 
reproductive tract. However, the vaginal cavity, as a targeted delivery site, poses several 
challenges due to individual variability of physiological conditions such as a range of pH, varied 
microbiota, cervical mucus and cyclic changes during both menstruation and pregnancy. 
Mucosal drug delivery systems, in particular, have been limited by the mucus barriers. The CVM 
structure is an interwoven mesh network of mucus laden with bacteria, proteins, lipids, 
polysaccharides and ions. All of these aspects contribute towards mucus as a barrier towards 
pathogens [38]. The structure of mucus also changes over time due to hormonal fluctuations 
[39]. An effective formulation must work to overcome these physiological challenges through a 
designed formulation model that promotes absorption through the mucosal pores and into the 
epithelium. Therefore, three factors become crucial in vaginal drug delivery: the rheological and 
gel like properties of the vehicle, size and subsequent stability of particles passing through the 
pores (as previously outlined), and the osmolality of the formulation. Here, I was primarily 
focused on describing a gel like formulation that with thermosensitive properties to create an in-
situ gel and promote extended release and absorption into the tissues and finding desirable strain 
characteristics that are similar to vaginal mucus which minimizes discomfort and secretions. 
Pluronic F127 has been used for thermosensitive polymers with reversible sol-gel transition 
behavior in aqueous solutions have been utilized for the vaginal delivery of a variety of drugs 
including 5-fluorouracil and metronidazole [40-41]. These gels provided a convenient and 
effective treatment. Furthermore, they have tunable properties and can easily be combined in a 




Pluronic F127 (12.6 kDa, 70% w/w PEO) was obtained from BASF (Mount Olive, NJ, USA) 
and used without further purification. Gels were prepared based on weight. Concentrations of 
Pluronic F127 are expressed by weight percentage (%, w/w). Pluronic polymer F127 was 
dissolved in deionized water and vortexed at room temperature. The solution was stored at 4 °C 
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overnight until the mixture was completely homogenous. This methodology was used to create 
ten F127 gels from 2-20% w/w.  
 
Rheological measurements of polymer gels were performed on a strain-controlled rheometer, 
Anton Paar MC 302, using parallel plate configuration. The plates were set with 1 mm height 
during measurements. Temperature control was achieved using the lower plate and humidity was 
maintained using a fluid bath (DI water) surrounding the outer cylinder with a solvent trap. The 
8mm plate geometry was loaded with the polymer solutions at 4 °C, in order to ensure that they 
were in the liquid state.  
 
The instrument was used in the oscillatory mode, in which the plate geometry is rotated 
sinusoidally at a given frequency. Amplitude sweeps were conducted at shear strain from 0.1 to 
1% strain. Frequency was measured at 0.1 to 100 rad/s. Temperature sweep measurements were 
performed at a constant heating rate of 1 °C/min until 50 °C. The frequency dependence of the 
complex modulus was determined between 0.01 and 100 rad/s. The sol-gel transition temperature 
of F127 gels was determined from an oscillatory shear temperature sweep at 1 rad/s. The sol-gel 
transition temperature was measured for all the gels. Finally, time sweeps measurements were 
performed at 25 °C and 37 °C for 10 mins.  
 
In vivo tests of in-situ gelation and distribution were conducted using fluorescent F127 gels. The 
gels were prepared with 5% w/w Alex Fluor labelled florescent F127 at an absorbance of 568 
and 95% w/w F127. The fluorescent gels were prepared by mass and mixed with deionized water 
at 6, 8, 10, 12, 14, 16 and 18% w/w.  
 
Female CF-1 mice of 6-8 weeks were sourced from Harlan (Indianapolis, IN). Housing and 
handling were performed in accordance to guidelines and experimental protocols as approved by 
the Johns Hopkins Animal Care and Use Committee. Prior to vaginal administration, mice were 
injected subcutaneously with 2.5 mg of medroxyprogesterone acetate [Depo-Provera (depo); 
Pfizer, NY, USA] in 100 µL of phosphate buffered saline (PBS) 7 days prior to experiments. 
Mice were anaesthetized with isoflurane and vaginally dosed with 20 µL or 50 µL of fluorescent 
F127. The mice were allowed to wake for 15 minutes. Vaginal swabs were taken from each 
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mouse and the gelation of the F127 was visually observed and recorded. Mice were then 
euthanized through cervical dislocation. The vagina, cervix and proximal uterine horns were 
excised. The tissues collected from mice treated vaginally with were flash frozen in Tissue-Tek 
O.C.T. (Sakura Finetex, USA) using liquid nitrogen vapor. All tissue samples were stored at -80 
°C until further analysis.  
 
Tissue sections were cut at 10 µm thickness and mounted on Superfrost Plus Microscope Slides 
(Fisher Scientific). Following cryogenic sectioning, slides were fixed in 10% w/v formalin 
solution, neutral buffered (Sigma Aldrich) for 10 min followed by two washes with PBS. Slides 
were then incubated in 1X TBS for 5 min followed by a PBS wash. ProLong Gold antifade 
mountant with DAPI (Life Technologies) was applied directly to samples. Slides were imaged 
using Confocal microscopy.  
 
Results and Discussion 
Rheological Properties of Pure F127 Gels  
 
Creating a vaginally compatible hydrogel requires understanding of the viscoelastic properties of 
the gel. Composition and concentration of gels can strongly affect rheology and lead to 
drastically different behavior. An oscillatory measurement system was employed because of its 
ability to measure both the elastic and viscous components. In order to measure the linear 
viscoelastic properties, we must find the linear viscoelastic region. The region was determined 
by measuring the storage (G’) and loss (G”) modulus as a function of the strain amplitude using 
a 20% w/w gel. The amplitude sweep was measured between 0.0001 and 2% strain at 1 rad/s. 
From Figure 6 A, I observed that G’ and G” are independent of strain amplitude up to 1.8. 
Therefore, a strain amplitude of 1.0 at 1 rad/s shear rate was used for all the subsequent 
measurements to remain in the linear region and maintain the internal structure of the gel during 
dynamic measurements.  
 
An ideal gel system would have rheological properties that increase the ease of application and 
the dispersion of gel across the vaginal canal. The gel should possess sufficiently viscous 
behavior that leads to retention in the mucus and offer elastic structure to facilitate sustained 
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release. Therefore, an in-situ gel that becomes physically entangled as temperature increases 
would improve application and have desirable viscoelastic characteristics. As early as 1945, Clift 
et al studied the rheological properties of vaginal mucus noting that flow-elasticity, plasticity and 
tack undergo significant changes throughout the menstrual cycle [42]. In 2003, Yoshida et al 
characterized human cervical mucus viscoelastic properties using various rheometric setups [43]. 
We also know based on ongoing pregnancy study that the properties of the CVM change as 
pregnancy progresses and the cervix ripens. Due to the high degree of variability in the CVM 
alone, without considering the effect of clearance rates and ambulation. Therefore, there is no 
single ideal viscosity value. As gels are non-Newtonian I determined a range of viscosities as a 
function of shear rate. Gels will experience a loss in viscosity at high shear rates if they have 
shear thinning behavior, as in Figure 6 D. The two-plate model provides a mathematical model 
for viscosity, where the lower plate is fixed and the upper plate drifts over the gel subjecting it to 
stress parallel to the upper surface. Viscosity on the Anton Paar system is based on 2 essential 
criteria: 
1. fluid has contact with both plates through adhesive forces; 
2. flow is laminar and turbulence is negligible.  
 
Correct loading of gel into the plate system reduces the chances of error and subsequent incorrect 
calculations. Shear stress is first calculated based on force per square unit area (Equation 2). 
Shear rate is then measured from the velocity (v) as rotational speed at various points, the shear 
gap (h) is known and can be used to find the shear rate (Equation 3). The viscosity is finally 

















Overall for all concentrations of F127 as the shear rate increases the viscosity decreases. Gels of 
16% up to 20% w/w start at a very high viscosity and decrease by almost two orders of 
magnitude at high shear rates at 50 s-1. 14% w/w F127 gel had a viscosity of 49.0 Pa s at a shear 
rate of 0.5 s-1 and decreased to 2.2 Pa s, indicating shear thinning behavior for all gels from 10 to 
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20% w/w. This pseudo-plastic flow behavior is characterized by a decreasing viscosity with 
increasing shear rate, thus as shear rate increases molecules in the hydrogel undergo 
disentanglement and the individual polymers have less flow resistance. Therefore, the gel would 
be suitable for vaginal delivery and still provide coating across the mucus at higher shear rates 
from the delivery medium.            
 
Since materials can display a mixture of both viscous and elastic behavior when sheared, 
viscoelastic behavior needs to be measured. Particular attention is paid to the elastic portion 
since it becomes more pronounced with faster movements (higher shear or frequency) and at 
lower temperatures. Under these two conditions the molecular network of a gel becomes more 
rigid. In contrast, higher temperatures and/or less motion allows gels to be more mobile and 
flexible. Thus, viscosity alone is insufficient as a metric for materials characterization as elastic 
effects can greatly determine the performance of a gel. Therefore, in addition to viscosity 
measurements and amplitude sweeps, frequency, temperature and time sweeps were conducted. 
Frequency tests indicated the viscoelastic behavior of the gel and provide a quantitative measure 
of the fluid dynamics of a given gel. The two-plate model allows us to measure shear stress 




[=]𝑃𝑎…………………………………………………………………………..Equation 5  
The oscillatory system allows a motor to move the top plate with a deflection of the upper plate 
at angles 0°, 90°, 180°, 270° and 360°. A maximum deflection and oscillatory period are 
evaluated as strain or deformation. The parameters for oscillatory tests present as a sine curve 
and from this we can find a maximum deflection or amplitude and its oscillatory period or 
frequency. This is where an amplitude determines the critical strain for a gel. Once this is found 
we can use the shear stress (measured by the counter force that acts on the lower plate). We 
obtain two resulting sinusoidal curves that have a phase shift δ, if viscoelastic. The phase shift 
for fluids are 90° ≥ δ ≥ 45°, while at rest. When δ = 0° the material has ideally elastic 
deformation behavior and when δ = 90° the material has ideally viscous flow behavior. Solids 
and gel like states have a phase shift of 45° ≥ δ ≥ 0°, at rest. Storage moduli (G’) represents the 
elastic portion which is quasi indicative of solid-state behavior. The loss modulus (G”) 
characterizes the viscous component. Internal friction from the components of a flowing fluid 
causes viscous behavior. The friction produces frictional heat and transforms deformation energy 
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to heat energy. Part of this energy is absorbed by the sample and this loss of energy is what 
defines the loss modulus. The storage modulus is defined by the elastic portion of energy that is 
stored in the deformed material.  
 
From our samples of F127 gels, the gels containing 12% w/w F127 had a higher loss to storage 
moduli ratio (G’>G”), meaning they were more fluid. And thus, could have weaker bonds 
between individual molecules. While gels greater than 14% w/w (up to 20% w/w) formed gels as 
indicated by the higher elastic modulus, indicating stronger physically bonding between 
molecules. Non-destructive deformation of the gel was seen at higher frequencies >30 rad/s for 
16, 18 and 20 % w/w gels. Gels below 14% w/w experienced inconsistent frequency behavior in 
the elastic modulus around the frequency range.  
 
The sol-gel transition temperature, and the elastic modulus of the F127 solutions were found to 
depend on the concentration of the polymer. Above the gel transition, the elastic modulus of the 
F127 gel plateaus with an increase in temperature. At lower F127 concentrations of 2%, 4% and 
6% w/w no definitive gelling could be determined, likely due to the higher water content. At gels 
between 8-12% w/w, gels achieved a sol-gel transition point between 27-30 °C before 







In vivo Gelation of Fluorescent F127 Gel  
 
The gelation of F127 hydrogels was in vivo confirmed by vaginally dosing mice. Gels of >10% 
w/w F127 converts to the gel phase at 37 °C when inserted vaginally. As seen in Figure 8, F127 
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aqueous solutions had a viscous gel like consistency on the vaginal swabs. Visual observation 
showed that viscosity increased with increasing concentration of F127. Gels of 6 and 8% w/w 
did not gel after the dosing procedure and remained liquid both intravaginally and on the swab 
after 15 minutes based on visual observation. Therefore, gels of higher concentrations, 10-20 % 
w/w, are more effectively become a gel in-situ and thus, are suited for vaginal dosing in mice 
(Figure 8).  
 
In terms of tissue distribution from confocal imaging, our hypothesis was the F127 hydrogel 
would along the surface area of the tissues and throughout the epithelia due to the nanoparticle 
size and the had better penetration through the reproductive tract. Gels of 16% had the greatest 












The rheological and gelation properties of Pluronic solutions can be impacted by the presence of 
various additive such as polymeric stabilizers and drug molecules. Therefore, when designing a 
hydrogel, it is imperative to test the gel’s physical properties with these additives. Most 
traditional polymer gels are formed through a swollen network of covalently crosslinked polymer 
chains. However, the Pluronic triblock copolymer is held by reversible entanglements of the 
coronae of neighboring micelles. The reversible nature of coronae entanglements is due to an 
absence of covalent crosslinking between micelles. The structure of these micelles into layers 
causes adaptive laminar shear flow and consequentially is responsible for the exceptional 
viscoelastic properties of Pluronic gel systems. Previous studies have shown that the viscoelastic 
properties are extremely resilient when subjected to shear forces. Therefore, the properties of 
F127 gels as previously demonstrated are dynamic and vary with shear rate and concentration. 
However, the organization of the physically linked micelles is changed with supplemental 
additives in the solution. Thus, it is important to further characterize the rheology of hydrogels 
loaded with nanoparticles or stabilizers.  
 
Hoffman, Ackerson and Loose pioneered work on shear induced transitions in suspensions of 
charged particles and subsequently the field studying the structural properties of colloidal 
crystals under shear has expanded significantly [43-44]. Recently, Jiang has shown that selective 
triblock copolyethers in an aqueous solution can lead to the formation of micelles with spherical 
core-shell geometry [45].  Dilute solutions typically contain discrete micelles, whereas highly 
concentrated solutions form highly ordered micelles. The packing order of these structures and 
their coronae can be influenced by environmental conditions such as higher shear and therefore, 
it is crucial to determine the physical limitations of each gel with NC and measure their 
effectiveness within the vaginal microenvironment.    
 
Methods  
Crinone® 8% gel (Allergan, Inc.) was obtained from Johns Hopkins Pharmacy. Pluronic® F127 
was obtained by BASF (Ludwigshafen, Germany). Progesterone (P8783-5G) was sourced from 
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Sigma-Aldrich. Pure F127 gels at a concentration of 14, 16, 18, 20% w/w were formulated as 
previously described. Solutions were kept at 4 °C until their next use. 8% progesterone 
nanoparticles were created using wet milling. Particle hydrodynamic diameter, polydispersity 
index (PDI), and surface charge (ζ-potential) of the progesterone NS formulations were 
measured using a Malvern Zetasizer Nano ZS (173° scattering angle). The NS were diluted 
1:1000 in 10 mM NaCl (pH 7) for ζ-potential measurements. The final NS formulation contained 
80 mg/ml progesterone (8%) in 2% w/w F127 and 2% w/w F68. Batches were milled for 10 h 
until the final average size of 260 nm was obtained. NS was separated from beads and 
lyophilized for 72 h. The final dry NS mass was then reconstituted with either the 14, 16, 18 or 
20% w/w F127 vehicle gel, forming a progesterone hydrogel.  
 
Physical Gel Measurements  
 
Hydrogels were then tested for physical characteristics including size, ζ-potential, osmolality and 
rheometry. Size, ζ-potential and polydispersity index measurements were carried out as 
previously described using dynamic light scattering on a Malvern Zetasizer Nano ZS. The 
tonicity of Crinone® and hydrogels was measured as previously described. Osmolality was 
measured using Wescor EliTechGroup Vapor vapor pressure Osmometer. The device was 
calibrated and 10 µL of undiluted hydrogel was measured. Additionally, the pH of F127 at 
various concentrations, Crinone® and progesterone loaded gels were measured using a Mettler 
Toledo pH meter. Rheological measurements of polymer gels were performed on a strain-
controlled rheometer, Anton Paar MC302, using parallel plate configuration. The plates were set 
with a distance of 1 mm during measurements. Temperature control was achieved using the 
lower plate and humidity was maintained using a fluid bath (DI water) surrounding the outer 
cylinder with a solvent trap. The 8 mm plate geometry was loaded with the polymer solutions at 
4 °C, in order to ensure that they were in the liquid state. The instrument was used in the 
oscillatory mode. Amplitude, frequency, temperature and viscosity measurements were 
conducted as previously described. 
 




Timed pregnant 6-8-week-old female CD-1 mice were ordered from the Charles River 
Laboratories (Wilmington, MA). Pregnant mice were delivered to the Johns Hopkins animal 
facility between 8 to 10 days of gestation (E8-E10). The mice were acclimated to a reverse light 
cycle room, with a dark period from 10 am – 10 pm) prior to conducting any procedures. All 
procedures began on E15 out of a total 19.6 day gestation period (range of 19-20 days). All 
procedures were approved by the Johns Hopkins Animal Care and Use Committee. I performed 
efficacy tests using a RU486 progesterone antagonist (Sigma-Aldrich M8046). RU486 was 
dissolved in dimethlysulfoxide (Sigma-Aldrich) at a concentration of 0.5 mg/mL. Pregnant mice 
were dosed subcutaneously in the scruff of the neck with 25 µg of RU486 in 100 µL on the 
morning of E15. Four distinct groups were maintained: control with no vaginal dosing, 
nanocrystal solution, NC hydrogel and Crinone®. The NC, hydrogel and Crinone® were all 
vaginally dosed. Two sets of efficacy experiments were performed with all four groups where 
the vaginal therapies were dosed with a total volume of 50 µL. Mice receiving the vaginal 
progesterone treatment were given 8 mg of progesterone using a 50 µL Wiretrol (Drummond 
Scientific) in the form of 50 µL of hydrogel, Crinone® gel or 50uL of the NS formulation.  The 
second set only compared NC hydrogel with Crinone® and RU486 antagonist alone, dosed at a 
volume of 20 µL of either nanoparticle loaded hydrogel or Crinone® gel. NS solutions were 
prepared up to 72 h prior to animal dosing. Treatment began at the time of RU486 injection and 
continued daily each morning until E18 or until PTB occurred. Mice did not receive further 
treatment if they delivered preterm, mice that remained pregnant throughout treatment received 
up to four doses. Animals were counted as delivered to term if the birth occurred after the night 
of E18 (E18.75 >day).  Upon analysis, statistical analysis of groups of three or more was 
conducted using the Log-rank test and the Fisher’s exact method for survival analysis in 
GraphPad Prism 8.  
 
Results and Discussion 
Rheological Properties  
 
Gel performance in vivo is strongly linked to the rheological properties of the gel. Spreading, 
retention and drug release behavior can be predicted based on rheological behavior. 
Comprehensive rheological characterization of drug delivery systems, as platforms and in mixed 
form, can provide drastically different results. In order to measure the linear viscoelastic 
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properties, we must find the linear viscoelastic region. The region was determined by measuring 
the storage (G’) and loss (G”) modulus as a function of the strain amplitude using a 20% w/w 
gel. The amplitude sweep was measured between 0.0001 and 1 at 1 rad/s. From Figure 10 A, I 
observed that G’ and G” are independent of strain amplitude up to 0.01%. Therefore, a strain 
amplitude of 0.001 at 1 rad/s shear rate was used for all the subsequent measurements to remain 
in the linear region and maintain the internal structure of the gel during dynamic measurements.  
 
In terms of viscosity, nanoparticle loaded gels at 16, 18 and 20 % w/w F127 had shear thinning 
behavior similar to F127 alone (Figure 10 B). However, 14 % w/w gel experienced a less 
discernable viscous behavior. 14 % w/w gel maintained its viscosity at lower strain rates before 
decreasing in viscosity at higher shear rates. While the viscosity of 20 % gel based on manual 
handling was difficult to use at room temperature. 16 and 18 % w/w presently are the best 
candidates for hydrogel in vivo delivery. Additionally, frequency sweeps were conducted with 
all two of the previous nanoparticles, selected based on the most favorable size, ζ-potential and 
stability data: 2% F127 coated particles and 2% F127 with 2% F68 coated nanoparticles. Both 
were mixed with 16% and 18% F127 gels based on weight. Both sets of particles and gels 
demonstrated fluid like behavior at low frequencies (G”>G’) and solid like behavior at higher 
frequencies (G’>G”). Both gels and nanoparticles experience irregular viscoelastic behavior at 
40 rad/s, the cause of which has not been determined.         
 
The temperature dependence of rheological properties of the gels was studied at a range of 20 °C 
to 50 °C. In Figure 11, I plotted the storage modulus as a function of temperature. For all 14, 16 
and 18% w/w hydrogels the storage modulus is low at lower temperatures but increases 
significantly with temperature, corresponding to the formation of gel. At the end of the sol-gel 
transition, the storage modulus becomes independent of the temperature. This is seen by the 
plateau of G’. At the higher concentration of 20 % w/w at 20 °C the gel has already formed 
therefore, in the rheological measurements the gels have already reached the end of the sol-gel 
transition and G’ begins to plateau around 25 °C (Figure 11). Furthermore, when comparing four 
formulations (2% F127 NP in 16 % F127 gel (1.16), 2% F127 & 2% F68 in 16 % F127 gel 
(3.16), 2% F127 NP in 18 % F127 gel (1.18) and 2% F127 & 2% F68 in 18 % F127 gel (3.18)) I 
found that both gels of 2% F127 and 2% F68 coated NP had a distinct crosslinking point from a 
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predominately fluid state (G”>G’) to a solid state (G’>G”). Formulation 3.16 as a lower 
concentration of F127 (16% w/w) experienced gelling at 29.4 °C while formulation 3.18 gelled 
at 23.0 °C. Both 2% F127 NP gels had a greater storage modulus to loss modulus at all 
temperatures from 20-50 °C (G’>G”) indicating a more solid state. The behavior of the 2% F127 
and 2% F68 coated NP is desired for an in vivo thermogelling drug system and suggests more 
tunable behavior than the 2% F127 NP gels. Thus 16% and 18% w/w F127 gels with 2% F127 
and 2% F68 NP would be suitable to move forward with in vivo application. 
 
Based on these results there is some but limited impact from the addition of 2% F127 and 2% 
F68 coated nanoparticles on the physical crosslinking and viscoelastic properties of the 
progesterone hydrogel. As determined by the amplitude sweep the linear viscoelastic region was 
defined from 0 to 1% strain. The structures of the 2% F127 and 2% F68 coated NP 16% F127 
hydrogel (herein referred to as NP gel), Crinone® and nanocrystal were further characterized 
using a frequency sweep below the critical strain γc. In frequency sweeps at 0.1% strain the 
hydrogel shows a more fluid-like behavior at high strain amplitudes where G”>G’ whereas they 
are more solid-like at low strains (G’>G”). The nanocrystal had inconsistent properties where 
both moduli oscillate without any dependence on the frequency (Figure 12). Overall, the 
hydrogel demonstrated a higher elastic modulus in comparison to Crinone®, possibly improving 
distribution throughout the CV tract. Consistent shear thinning behavior similar to Crinone® and 
substantially improved from nanocrystal alone. Gels at 18-20% w/w at a higher viscosity than 
Crinone®, however gels of 14-16% w/w had a similar viscosity and displayed desired shear 










Other Physical Properties  
 
It has been found that the pH of Crinone® (3.2) was similar to the vaginal microenvironment 
which ranges from 3.5 ± 0.3 [46]. The mucoinert progesterone NPs alone was 7.2 and NPs in 
F127 ranged from 6.88 to 7.02 as seen in Table 2. In the future adding excipients such as 
carbonate derivatives or lactic acid to reduce the pH might improve the in vivo performance of 
the gel. We were also able to determine the tonicities of NP gel and Crinone®, 144 and 1560 
mOsm/kg, respectively. While our NP gel is hypotonic this is an improvement from Crinone® 
which is hypertonic. In this case the osmolarity of our gel could be optimized to improve the net 
flow of fluid into the vaginal epithelia.  
 
pH  
Type of Particle  
1 2 3 4 
Gel % w/w 2% F127 
2% F127 + 
2% TPGS  
2% F127 + 
2% F68 
2% F127 + 
2% HS15 
14 6.88 6.93 6.93 6.92 
16 6.93 6.96 6.96 6.93 
18 6.93 6.98 7.02 6.92 
20 6.99 7.02 6.99 6.88 
Crinone®  3.24       
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Table 2: Average pH of various progesterone gel formulations. The pH of a market approved therapy Crinone® is drastically 
lower in comparison to formulated NP based F127 hydrogels.  
 
RU486 Efficacy  
 
RU486, or Mifepristone, is a well-studied competitive progesterone receptor antagonist, which 
provides us with a functional progesterone withdrawal model. As reported by Hoang et al a dose 
of 25 µg RU486 via subcutaneous injection is resulted in preterm birth in 85% of control animals 
within 24 h [36]. 50 µg RU486 in 100 µL was dosed to all mice. All control mice gave preterm 
within 24 h at E16. Here we observed that 8 % progesterone delivered at a volume of 50 µL 
could oppose the effects of RU486 in mice. This was observed in both in the nanocrystal 
formulation as well as the 18 % w/w F127 progesterone loaded gel. At E19 both progesterone 
nanocrystal and progesterone hydrogel had 37.5% of mice remain pregnant. Comparatively, 
Crinone® was less effective with 28.6% of pregnancies maintained at E19 (Figure 11 A). At a 
lower volume of 20 µL of gel vaginal therapies at 8 % progesterone, the gel nanoparticle was 
less effective than Crinone®, with only one third of mice remaining pregnant at E19. Crinone® 
gel was able to prevent over 50% of preterm births. While neither result was statistically 
significant, the variation in these results could be due to a number of conditions including the pH 
of the gel and the decrease in gel concentration from 18% to 16%. Furthermore, both domestic 
and wild mice seasonally experience changes in breeding and the gestation stages as reported by 
Drickamer et al [47]. The seasonal variation can result in reduced pup size, decreased viability, 
lower litter sizes over winter months in comparison to the fall, spring and summer. It is 
hypothesized that shifting rates of breeding and pregnancy could be a natural mechanism to 
account for resource availability and climate conditions. Decreased efficacy in the 20 µL dosed 
progesterone gel RU486 antagonist experiment may be partially due to the overall diminished 










Overall, I was able to define the properties of a potential candidate hydrogel for vaginal drug 
delivery. From more than 90 unique combinations of milled progesterone loaded nanoparticles I 
found five with a near neutral ζ-potential, with a hydrodynamic diameter of less than 300 nm and 
a PDI below 0.25.  
 
As a stand-alone gel, F127 was characterized for physical properties. Both the 2% F127 
progesterone loaded nanocrystals and the 2% F127 progesterone nanocrystals with additional 2% 
w/w Pluronic F68 stabilizer demonstrated the greatest stability. Furthermore, I found that 
solutions of 14-20% (w/w) F127 demonstrated desirable rheological properties in terms of 
viscosity, gelation, shear thinning behavior and viscoelastic dynamics.  Pluronic F127 based 
hydrogel also had similar or improved elastic properties compared to Crinone® and to the 
nanoparticle suspension. I found that both the 16 and 18% w/w progesterone hydrogels were 
hypotonic and demonstrated Crinone® had toxicity in mice likely due to the hypertonicity. 
However, the pH of the hydrogel could be optimized to improve in vivo efficacy. I was able to 
successfully create a gel formulation that would be safer for chronic daily use and showed 






1. Kinney, M. V., Lawn, J. E., Howson, C. P., & Belizan, J. (2012). 15 million preterm 
births annually: What has changed this year? Reproductive Health, 9(1), 2–5. 
http://doi.org/10.1186/1742-4755-9-28 
2. P.K. Shah, V. Prabhu, S.S. Karandikar, R. Ranjan, V. Narendran, N. Kalpana, 
Retinopathy of prematurity: Past, present and future, World journal of clinical pediatrics, 
5 (2016) 35-46. 
3. Malaeb S, Dammann O. Fetal Inflammatory Response and Brain Injury in the Preterm 
Newborn. Journal of child neurology. 2009;24(9):1119-1126. 
doi:10.1177/0883073809338066. 
4. Simmons, L. V. E., Rubens, C. E., Darmstadt, G. L., & Gravett, M. G. (2010). Preventing 
Preterm Birth and Neonatal Mortality: Exploring the Epidemiology, Causes, and 
Interventions. Seminars in Perinatology, 34(6), 408–415. 
http://doi.org/10.1053/j.semperi.2010.09.005 
5. B.M. Kuehn, Groups take aim at us preterm birth rate, JAMA, 296 (2006) 2907-2908. 
6. S.S. Hassan, R. Romero, D. Vidyadhari, S. Fusey, J.K. Baxter, M. Khandelwal, J. 
Vijayaraghavan, Y. Trivedi, P. Soma-Pillay, P. Sambarey, A. Dayal, V. Potapov, J. 
O'Brien, V. Astakhov, O. Yuzko, W. Kinzler, B. Dattel, H. Sehdev, L. Mazheika, D. 
Manchulenko, M.T. Gervasi, L. Sullivan, A. Conde-Agudelo, J.A. Phillips, G.W. Creasy, 
Vaginal progesterone reduces the rate of preterm birth in women with a sonographic 
short cervix: a multicenter, randomized, double-blind, placebo-controlled trial, 
Ultrasound in obstetrics & gynecology : the official journal of the International Society of 
Ultrasound in Obstetrics and Gynecology, 38 (2011) 18-31. 
7. Whaley, K. J., Hanes, J., Shattock, R., Cone, R. A., & Friend, D. R. (2010). Novel 
Approaches to Vaginal Delivery and Safety of Microbicides: Biopharmaceuticals, 
Nanoparticles, and Vaccines. Antiviral Research, 88(SUPPL.), S55–S66. 
http://doi.org/10.1016/j.antiviral.2010.09.006 
8. Lai, S. K., Wang, Y.-Y., Hida, K., Cone, R., & Hanes, J. (2010). Nanoparticles reveal 
that human cervicovaginal mucus is riddled with pores larger than viruses. Proceedings 
of the National Academy of Sciences, 107(2), 598 LP-603. Retrieved from 
http://www.pnas.org/content/107/2/598.abstract 
9. Vermani, K., & Garg, S. (2000). The scope and potential of vaginal drug delivery. 
Pharmaceutical Science and Technology Today, 3(10), 359–364. 
http://doi.org/10.1016/S1461-5347(00)00296-0 
10. Smith-Dupont, K. B., Wagner, C. E., Witten, J., Conroy, K., Rudoltz, H., Pagidas, K., … 
Ribbeck, K. (2017). Probing the potential of mucus permeability to signify preterm birth 
risk. Scientific Reports, 7(1), 1–14. http://doi.org/10.1038/s41598-017-08057-z 
11. Romero, R., Dey, S. K., & Fisher, S. J. (2014). Preterm labor: One syndrome, many 
causes. Science, 345(6198), 760 LP-765. Retrieved from 
http://science.sciencemag.org/content/345/6198/760.abstract 
12. Lai, S. K., O’Hanlon, D. E., Harrold, S., Man, S. T., Wang, Y.-Y., Cone, R., & Hanes, J. 
(2007). Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. 




13. G.C. Di Renzo, I. Giardina, G. Clerici, E. Brillo, S. Gerli, Progesterone in normal and 
pathological pregnancy, Horm Mol Biol Clin I, 27 (2016) 35-48. 
14. Patel, B., Elguero, S., Thakore, S., Dahoud, W., Bedaiwy, M., & Mesiano, S. (2015). 
Role of nuclear progesterone receptor isoforms in uterine pathophysiology. Human 
Reproduction Update, 21(2), 155–173. http://doi.org/10.1093/humupd/dmu056 
15. Ilicic, M., Zakar, T., & Paul, J. W. (2017). Modulation of Progesterone Receptor Isoform 
Expression in Pregnant Human Myometrium. BioMed Research International, 2017. 
http://doi.org/10.1155/2017/4589214 
16. Smart, S., Singal, A., & Mindel, A. (2004). Social and sexual risk factors for bacterial 
vaginosis. Sexually Transmitted Infections, 80(1), 58–62. 
http://doi.org/10.1136/sti.2003.004978 
17. Forray, A. (2016). Substance use during pregnancy. F1000Research, 5(May), 887. 
http://doi.org/10.12688/f1000research.7645.1 
18. J.M. O'Brien, C.D. Adair, D.F. Lewis, D.R. Hall, E.A. Defranco, S. Fusey, P. Soma-
Pillay, K. Porter, H. How, R. Schackis, D. Eller, Y. Trivedi, G. Vanburen, M. 
Khandelwal, K. Trofatter, D. Vidyadhari, J. Vijayaraghavan, J. Weeks, B. Dattel, E. 
Newton, C. Chazotte, G. Valenzuela, P. Calda, M. Bsharat, G.W. Creasy, Progesterone 
vaginal gel for the reduction of recurrent preterm birth: primary results from a 
randomized, double-blind, placebo-controlled trial, Ultrasound in obstetrics & 
gynecology : the official journal of the International Society of Ultrasound in Obstetrics 
and Gynecology, 30 (2007) 687-696. 
19. Batrakova, E. V, & Kabanov, A. V. (2008). Pluronic block copolymers : Evolution of 
drug delivery concept from inert nanocarriers to biological response modi fi ers. Journal 
of Controlled Release, 130(2), 98–106. https://doi.org/10.1016/j.jconrel.2008.04.013 
20. Ensign LM, Lai SK, Wang YY, et al. Pretreatment of human cervicovaginal mucus with 
pluronic F127 enhances nanoparticle penetration without compromising mucus barrier 
properties to herpes simplex virus. Biomacromolecules. 2014;15(12):4403–4409. 
doi:10.1021/bm501419z 
21. Cornaire, G., Woodley, J., Hermann, P., Cloarec, A., Arellano, C., & Houin, G. (2004). 
Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo, 
278, 119–131. https://doi.org/10.1016/j.ijpharm.2004.03.001 
22. Huang, J., Si, L., Jiang, L., Fan, Z., Qiu, J., & Li, G. (2008). Effect of pluronic F68 block 
copolymer on P-glycoprotein transport and CYP3A4 metabolism, 356, 351–353. 
https://doi.org/10.1016/j.ijpharm.2007.12.028 
23. Zhang, Z., Tan, S., & Feng, S. (2012). Biomaterials Vitamin E TPGS as a molecular 
biomaterial for drug delivery. Biomaterials, 33(19), 4889–4906. 
https://doi.org/10.1016/j.biomaterials.2012.03.046 
24. Yang C, Wu T, Qi Y, Zhang Z. Recent Advances in the Application of Vitamin E TPGS 
for Drug Delivery. Theranostics. 2018;8(2):464–485. Published 2018 Jan 1. 
doi:10.7150/thno.22711 
25. Amin, Md Lutful. “P-glycoprotein Inhibition for Optimal Drug Delivery.” Drug target 
insights vol. 7 27-34. 19 Aug. 2013, doi:10.4137/DTI.S12519 
26. R.A.Shirwaiker, M.F.Purser, R. A. W. (2014). Scaffolding hydrogels for rapid 




27. Pitto-Barry, A., & Barry, N. P. E. (2014). Pluronic block-coplymers in medicine: from 
chemical and biological versatility to rationalization and clinical advances, 5(10). 
https://doi.org/10.1039/c4py00039k 
28. Hu, L., Zhang, J., Zhu, C., Pan, H., & Liu, H. (2017). Effect of the additives on clouding 
behavior and thermodynamics of coenzyme Q10-Kolliphor HS15 micelle aqueous 
solutions, 687, 264–269. https://doi.org/10.1016/j.cplett.2017.09.032 
29. “VITAMIN E TPGS: D-Alpha-Tocopheryl Polyethylenglycol 1000 Succinate.” Vitamin 
E TPGS, Tocofersolan, Antares, www.parmentier.de/gpfneu/english/tpgs.php. 
30. “Pluronic F-68.” PhytoTechnology Laboratories, phytotechlab.com/pluronic-f-68.html. 
31. Olmsted, Stuart S., et al. "Diffusion of macromolecules and virus-like particles in human 
cervical mucus." Biophysical journal 81.4 (2001): 1930-1937. 
32. Lai SK, Wang YY, Hida K, Cone R, Hanes J. Nanoparticles reveal that human 
cervicovaginal mucus is riddled with pores larger than viruses [published correction 
appears in Proc Natl Acad Sci U S A. 2011 Aug 23;108(34):14371]. Proc Natl Acad Sci 
U S A. 2009;107(2):598–603. doi:10.1073/pnas.0911748107 
33. Ensign LM, Henning A, Schneider CS, et al. Ex vivo characterization of particle 
transport in mucus secretions coating freshly excised mucosal tissues. Mol Pharm. 
2013;10(6):2176–2182. doi:10.1021/mp400087y 
34. Lai SK, et al. Rapid transport of large polymeric nanoparticles in fresh undiluted human 
mucus. Proc Natl Acad Sci U S A. 2007;104(5):1482–1487. 
35. Burroughs Wellcome Fund 
36. Hoang, T., Zierden, H., Date, A., Ortiz, J., & Gumber, S. (2019). Development of a 
mucoinert progesterone nanosuspension for safer and more e ff ective prevention of 
preterm birth. Journal of Controlled Release, 295(October 2018), 74–86. 
https://doi.org/10.1016/j.jconrel.2018.12.046 
37. Ensign, Laura M., et al. "Enhanced vaginal drug delivery through the use of hypotonic 
formulations that induce fluid uptake." Biomaterials 34.28 (2013): 6922-6929. 
38. Cone, Richard A. "Barrier properties of mucus." Advanced drug delivery reviews 61.2 
(2009): 75-85. 
39. Bilensoy E, Çırpanlı Y, Şen M, Doğan AL, Çalış S. Thermosensitive mucoadhesive gel 
formulation loaded with 5-Fu: cyclodextrin complex for HPV-induced cervical cancer. J 
Incl Phenom Macrocycl Chem. 2007;57(1–4):363–370. doi: 10.1007/s10847-006-9259-y. 
40. el Ibrahim SA, Ismail S, Fetih G, Shaaban O, Hassanein K, Abdellah NH. Development 
and characterization of thermosensitive pluronic-based metronidazole in situ gelling 
formulations for vaginal application. Acta Pharm. 2012;62(1):59–70. doi: 
10.2478/v10007-012-0009-y. 
41. Clift, Arthur Frederick. "Observations on certain rheological properties of human cervical 
secretion." (1945): 1-9. 
42. Yoshida, Kohji, et al. "Rheology of human cervical mucus--with special reference to 
measurement of viscoelasticity using various rheometers." Journal of UOEH 25.3 (2003): 
317-324. 
43. Ackerson, Bruce J. "Shear induced order and shear processing of model hard sphere 
suspensions." Journal of Rheology 34.4 (1990): 553-590. 
44. Chen, L. B., B. J. Ackerson, and C. F. Zukoski. "Rheological consequences of 




45. Jiang, J., Burger, C., Li, C., Li, J., Lin, M. Y., Colby, R. H., … Sokolov, J. C. (2007). 
Shear-Induced Layered Structure of Polymeric Micelles by SANS. Macromolecules, 
40(11), 4016–4022. https://doi.org/10.1021/ma062654j 
46. O’Hanlon, Deirdre E., Thomas R. Moench, and Richard A. Cone. "Vaginal pH and 
microbicidal lactic acid when lactobacilli dominate the microbiota." PloS one 8.11 
(2013): e80074. 
47. Drickamer, L. C. "Seasonal variation in fertility, fecundity and litter sex ratio in 
laboratory and wild stocks of house mice (Mus domesticus)." Laboratory animal 
science 40.3 (1990): 284-288 
48. Dawson M, Wirtz D, Hanes J. Enhanced viscoelasticity of human cystic fibrotic sputum 







VICTORIA E. LANEY 
 






MSE Johns Hopkins University, Chemical and Biomolecular Engineering  May 2019 
Thesis: “The Development of Thermoreversible Progesterone-Loaded Hydrogels for the 
Prevention of Preterm Birth” 
 Advisor: Dr. Laura Ensign 
 
BS Johns Hopkins University, Chemical and Biomolecular Engineering May 2016 
 Molecular and Cellular Bioengineering Concentration 
 
HONORS AND AWARDS 
 
Tocris Bioscience Scholarship 2018 
Chemical and Biomolecular Engineering Master Scholarship 2018 
GEMS Student Travel Award 2018 
Dean’s Fellowship 2017 
Institute for Nanobiotechnology IRES 2015 
Provost Undergraduate Research Award 2012 
Mattie and George Newman Memorial Scholarship 2013 
Terence Flannery Memorial Annual Scholarship 2013 
American Foreign Service Association Merit Award 2012 




Johns Hopkins University, George Mason University, La Sierra Bolivia  2018 to 2019 
Advisor: Dr. Amanda Debes 
• Developed a nanocage hydrogel to target tuberculosis antigens in vitro from pediatric 
urine samples while at George Mason University  
• Optimized reactive blue and reactive black dot blots for the detection of tuberculosis 
antigens and subsequent development of a point-of-care lateral flow assay  
• Collected and analyzed clinical samples from suspected tuberculosis cases in Bolivia  
 
Thesis, Johns Hopkins University, Baltimore MD  2017 to 2019 
Advisor: Dr. Laura Ensign 
• Developed progesterone hydrogel formulations that would rapidly penetrate 
cervicovaginal mucus in pregnant women  
 
 38 
• Tested the mechanism of inflammation in mouse models through supplementation with 
progesterone and trichostatin A  
• Characterized the structural and barrier properties of women’s cervicovaginal mucus 
during pregnancy 
 
US Centers for Disease Control & Prevention, Yaoundé Cameroon 2017 
HIV Treatment Associate 
• Conducted hospital visits with implementing partners to ensure quality of patient care and 
gathered baseline data for key indicators to enable measurement of progress   
• Analyzed patient data using Excel and MATLAB to find errors in patient treatment and 
inefficiencies in care sites and created a linkage model for the FY18 country operation 
plan  
• Trained clinical staff in the delivery of key population services and developed standard 
operating procedures on HIV/AIDS treatment  
 
Sanaria Inc. & Protein Potential, Rockville MD 2016 to 2017 
Research Associate  
• Led a team of researchers and scientists in the formulation, manufacture and analysis of a 
Phase 1 foam dried drug to treat anthrax, typhoid and shigellosis    
• Manufactured a novel vaccine for malaria in a GMP facility using aseptic technique, 
cGMP, GCP, GDP for Phase 2 and 3 clinical trials  
• Developed a new method of cryopreservation and long-term stability for live vaccines 
through flash freezing  
 
Interuniversity Microelectronics Center (imec), Leuven Belgium 2015 
Engineering Research Intern 
• Characterized the metastatic process of LNCaP and MDA-MB-231 cells using lens free 
imaging  
• Fabricated microfluidic devices in an ISO 3 cleanroom using sterile technique for cancer 
mobility assays  
• Developed an automated cell tracking method in MATLAB to process wound healing 
assays  
 
Johns Hopkins University, Baltimore MD 2013 to 2016 
Advisor: Dr. Konstantinos Konstantopoulos 
• Awarded the Provost Undergraduate Research Award to determine breast cancer decision 
making in branched microchannels  
• Tested the effect of anti-adhesion drugs on cancer cell migration in microfluidic 
chambers resembling vasculature  
• Conducted experiments to understand the novel signaling mechanisms of cancer cells 




Arbor Tutors, Baltimore MD May 2018 to present 
 
 39 
Tutoring Instructor, SAT and GRE Mathematics 
• Developed individualized syllabi and lesson plans for students 
• Taught several students math topics including but not limited algebra, geometry, 
introductory calculus, statistics and probability 
 
InnoWorks, Baltimore MD September 2012 to May 2015 
Tutor, General Science & Mathematics  
• Tutored students on a weekly basis on middle school math and science 
• Developed coursework and relevant learning materials for a week-long summer camp for 
middle school students 
• Taught students about basic science including simple physics (kinematics and optics), 






Paul, C. Shea, D. Mahoney, M. Laney, V. Chai, A. W.-C. Hung, Konstantopoulos, K. 
The Interplay of the Physical Microenvironment, Contact Guidance and Cell Signaling in 
Cell Decision Making (2016) The FASEB Journal 
 
Conference Proceedings  
 
Laney, V. Zierden, H. Hernandez, N. Bensouda, S. Ensign, L. Rheological Properties of 
Thermoreversible Nanoparticle Hydrogels for Vaginal Drug Delivery (2018) 
Indianapolis, IN 
 
Laney, V. Huang, H. Wu, Y. Jackson, J. Li, M. Gao, L. Xu, R. Chakravarty, S. Sim, KL. 
James, E. Stabilization of the recombinant Ty21a-vectored vaccine, TyOraSs, against 
Shigellosis by foam drying (2017) Washington DC  
 
Laney, V. Paul, C. Chai, A. MDA-MB-231 Breast Cancer Decision Making in Y-Shaped 
Microchannels (2015) Baltimore, MD  
 
Laney, V. Mathieu, E. Analysis of LNCaP and MDA-MB-231 Motility Using Lens-Free 




Pharmacology Course, Foundation for Advanced Education in the Sciences, 2017 
 
Aseptic Technique Workshop, Sanaria Inc., 2017 
 








American Institute of Chemical Engineers 
National Society of Black Engineers 





Symposium Founder and Co-Organizer 
Johns Hopkins Institute NanoBiotechnology Undergraduate Research Symposium 
• “Frontiers of Medicine: Biological & Engineering Research Driving the State of Health 
Care” November 10, 2016 




English: Native Language 
 





Applications: ASPEN, GraphPad 
 
 
 
 
 
 
 
 
